@article{article, title = {{Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective}},
url = {{}},
year = {{2010}},
month = {{5}},
author = {{Sofrygin O and Delea TE and Tappenden P and Karnon J and Browning D and Amonkar M and Lykopoulos K and Cameron DA}},
doi = {{10.1200/jco.2010.28.15_suppl.6037}},
volume = {{28}},
journal = {{JOURNAL OF CLINICAL ONCOLOGY}},
issue = {{15}},
note = {{Accessed on 2025/07/12}}}